S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
The gold catalyst we’ve waited for (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
The gold catalyst we’ve waited for (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
The gold catalyst we’ve waited for (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Modern Day Options Trading For Beginners! (Ad)pixel
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Modern Day Options Trading For Beginners! (Ad)pixel
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
The gold catalyst we’ve waited for (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
NASDAQ:LYEL

Lyell Immunopharma - LYEL Stock Forecast, Price & News

$2.01
-0.02 (-0.99%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.95
$2.03
50-Day Range
$1.97
$3.48
52-Week Range
$1.83
$8.74
Volume
964,807 shs
Average Volume
1.21 million shs
Market Capitalization
$501.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.67

Lyell Immunopharma MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
231.7% Upside
$6.67 Price Target
Short Interest
Bearish
15.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.31mentions of Lyell Immunopharma in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.15) to ($1.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

841st out of 1,005 stocks

Pharmaceutical Preparations Industry

406th out of 486 stocks


LYEL stock logo

About Lyell Immunopharma (NASDAQ:LYEL) Stock

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Stock News Headlines

Lyell Immunopharma (NASDAQ:LYEL) Hits New 12-Month Low at $1.83
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 3.5%
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Lyell Immunopharma CEO Liz Homans Steps Down; Names Lynn Seely Replacemet
See More Headlines
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Company Calendar

Last Earnings
2/28/2023
Today
3/26/2023
Next Earnings (Estimated)
5/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LYEL
Fax
N/A
Employees
219
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.67
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+231.7%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-183,120,000.00
Net Margins
-216.24%
Pretax Margin
-216.24%

Debt

Sales & Book Value

Annual Sales
$84.68 million
Book Value
$3.34 per share

Miscellaneous

Free Float
185,210,000
Market Cap
$501.72 million
Optionable
Not Optionable
Beta
-1.68

Key Executives

  • Dr. Richard D. Klausner M.D. (Age 70)
    Founder & Exec. Chairman
    Comp: $510.17k
  • Ms. Elizabeth Homans (Age 56)
    CEO & Director
    Comp: $988.85k
  • Mr. Charles W. Newton (Age 51)
    Chief Financial Officer
    Comp: $1.75M
  • Mr. Stephen J. Hill (Age 52)
    Chief Operating Officer
    Comp: $808.12k
  • Prof. Stanley R. Riddell M.D.
    Founder & Scientific Advisor
  • Dr. Crystal L. Mackall M.D.
    Founder & Scientific Advisor
  • Nellie Dillery
    Director of Accounting
  • Mr. Richard Goold Ph.D. (Age 62)
    Chief Information Officer
  • Dr. Gary Lee Ph.D. (Age 45)
    Chief Scientific Officer
  • Ellen Rose
    VP of Communications & Investor Relations













LYEL Stock - Frequently Asked Questions

Should I buy or sell Lyell Immunopharma stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" LYEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LYEL, but not buy additional shares or sell existing shares.
View LYEL analyst ratings
or view top-rated stocks.

What is Lyell Immunopharma's stock price forecast for 2023?

3 Wall Street analysts have issued 1 year price objectives for Lyell Immunopharma's stock. Their LYEL share price forecasts range from $4.00 to $9.00. On average, they anticipate the company's share price to reach $6.67 in the next twelve months. This suggests a possible upside of 231.7% from the stock's current price.
View analysts price targets for LYEL
or view top-rated stocks among Wall Street analysts.

How have LYEL shares performed in 2023?

Lyell Immunopharma's stock was trading at $3.47 at the beginning of 2023. Since then, LYEL stock has decreased by 42.1% and is now trading at $2.01.
View the best growth stocks for 2023 here
.

When is Lyell Immunopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our LYEL earnings forecast
.

How were Lyell Immunopharma's earnings last quarter?

Lyell Immunopharma, Inc. (NASDAQ:LYEL) issued its quarterly earnings results on Tuesday, February, 28th. The company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.28. The firm had revenue of $48.39 million for the quarter, compared to analyst estimates of $2.85 million. Lyell Immunopharma had a negative trailing twelve-month return on equity of 21.53% and a negative net margin of 216.24%.

When did Lyell Immunopharma IPO?

(LYEL) raised $425 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO.

What is Lyell Immunopharma's stock symbol?

Lyell Immunopharma trades on the NASDAQ under the ticker symbol "LYEL."

Who are Lyell Immunopharma's major shareholders?

Lyell Immunopharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.47%), Geode Capital Management LLC (1.22%), Charles Schwab Investment Management Inc. (0.45%), Baillie Gifford & Co. (0.31%), Bank of America Corp DE (0.26%) and JPMorgan Chase & Co. (0.23%). Insiders that own company stock include Cathy Friedman and Richard Klausner.
View institutional ownership trends
.

How do I buy shares of Lyell Immunopharma?

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lyell Immunopharma's stock price today?

One share of LYEL stock can currently be purchased for approximately $2.01.

How much money does Lyell Immunopharma make?

Lyell Immunopharma (NASDAQ:LYEL) has a market capitalization of $501.72 million and generates $84.68 million in revenue each year. The company earns $-183,120,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does Lyell Immunopharma have?

The company employs 219 workers across the globe.

How can I contact Lyell Immunopharma?

The official website for the company is www.lyell.com. The company can be reached via phone at 650-695-0677 or via email at erose@lyell.com.

This page (NASDAQ:LYEL) was last updated on 3/26/2023 by MarketBeat.com Staff